Abstract |
Ketoconazole (aronazole manufactured by Janssen Pharmaceutica, Belgium) was used in the therapy of 29 patients with mycoses of the organ of vision, 5 of these with mycotic canaliculitis, 5 with mycotic conjunctivitis, 13 with keratomycosis, and 6 with mycotic endophthalmitis. The patients were administered 1 tablet of oronazole (200 mg of ketoconazole) daily usually for 2-3 weeks. In 6 cases with severe keratomycoses ketoconazole emulsion was additionally administered 5-6 times daily into the eye (in drops). 19 patients (including all those with keratomycosis) were cured, in 5 cases the clinical status improved, in another 5 no effect was achieved. No side effects were recorded. These data are in accord with the literature reports on the high efficacy of ketoconazole in the treatment of mycotic involvement of the organ of vision and on the high antimycotic spectrum of this drug.
|
Authors | Iu F Maĭchuk, M K Karimov, N A Lapshina |
Journal | Vestnik oftalmologii
(Vestn Oftalmol)
1990 Jan-Feb
Vol. 106
Issue 1
Pg. 44-6
ISSN: 0042-465X [Print] Russia (Federation) |
Vernacular Title | Ketokonazol v lechenii mikozov glaza. |
PMID | 2378037
(Publication Type: English Abstract, Journal Article)
|
Chemical References |
- Emulsions
- Tablets
- Ketoconazole
|
Topics |
- Drug Evaluation
- Emulsions
- Eye Infections, Fungal
(drug therapy, microbiology)
- Fungi
(isolation & purification)
- Humans
- Ketoconazole
(adverse effects, therapeutic use)
- Tablets
|